<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003016</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065596</org_study_id>
    <secondary_id>ATLAS</secondary_id>
    <secondary_id>EU-96064</secondary_id>
    <nct_id>NCT00003016</nct_id>
  </id_info>
  <brief_title>Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer</brief_title>
  <official_title>Reliable Assessment of the Efficacy and Safety of Prolonging the Use of Adjuvant Tamoxifen: A Large, Simple, Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using&#xD;
      tamoxifen may fight breast cancer by reducing the production of estrogen. It is not yet known&#xD;
      if prolonged tamoxifen is more effective than shorter tamoxifen therapy following curative&#xD;
      treatment for breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying giving tamoxifen over a prolonged period&#xD;
      of time to see how well it works compared to giving tamoxifen over a shorter period of time&#xD;
      in treating patients who have had a breast tumor removed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the balance of risks and benefits in prolonging the duration of adjuvant&#xD;
           tamoxifen by at least 5 years in patients with curatively treated breast cancer who have&#xD;
           already had about 5 years of adjuvant tamoxifen.&#xD;
&#xD;
      OUTLINE: This is a randomized study. After about 5 years of adjuvant tamoxifen,&#xD;
      recurrence-free patients are randomized to stop tamoxifen treatment immediately or to&#xD;
      continue tamoxifen treatment for at least 5 more years.&#xD;
&#xD;
      Patients are followed annually.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 20,000 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 1995</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (i.e., all-cause mortality)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specific-cause mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of second primary tumors</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Curatively treated carcinoma of the breast&#xD;
&#xD;
          -  Currently taking adjuvant tamoxifen&#xD;
&#xD;
               -  Must be substantial uncertainty as to whether or not to continue tamoxifen (i.e.,&#xD;
                  no clear indication or definite contraindication to further treatment with&#xD;
                  tamoxifen)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No contraindications to receiving tamoxifen&#xD;
&#xD;
          -  No other serious medical problems&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior biologic therapy allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Prior chemotherapy allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior radiotherapy allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior surgery allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Arriagada, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlas Trial Office</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>OX2 6HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

